Zeng et al. [87] reported that the use of AMD3100 (a highly specific CXCR4 antagonist) to inhibit the CXCL12/CXCR4 axis in ovarian cancer decreased intratumoral Treg infiltration, increased effector T-cell infiltration, and promoted the polarization of M2 to M1 macrophages in the tumor. Here, CXCR4 is linked to ovarian carcinoma.